Search
Close this search box.
×
Search
[custom_company_search_form]
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,584.61
(0.42%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,584.61
(0.42%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,584.61
(0.42%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,584.61
(0.42%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,584.61
(0.42%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,584.61
(0.42%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,584.61
(0.42%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,584.61
(0.42%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,584.61
(0.42%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,584.61
(0.42%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)

Stock Piper AI Index

Stock Piper AI Index

Subscribe
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,584.61
(0.42%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,584.61
(0.42%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,584.61
(0.42%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,584.61
(0.42%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,584.61
(0.42%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,584.61
(0.42%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,584.61
(0.42%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,584.61
(0.42%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,584.61
(0.42%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,584.61
(0.42%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)

Neuren Pharmaceuticals Ltd

NEU

ASX

Neuren Pharmaceuticals Limited (NEU) is a biopharmaceutical firm dedicated to advancing therapies for brain injury, neurodevelopmental, and neurodegenerative disorders. At the forefront of their research are two pivotal drug products: NNZ-2566 and NNZ-2591. Operating across New Zealand, Australia, and the USA, NEU is strategically positioned to drive forward its mission of developing effective treatments that address critical neurological conditions on a global scale.

Latest Posts

Line Chart with Gradient
Price
$12.360
-0.07 (-0.56%)
At Close 22/11 (AEST)
Related Companies
CHALLENGER LIMITED
$CGF
AMP LIMITED
$AMP
EILDON CAPITAL GROUP
$EDC
CHANGE FINANCIAL LIMITED
$CCA
PROPELL HOLDINGS LIMITED
$PHL

Leave a Comment on NEU


Comments for NEU

    Latest Posts

    Neuren Pharmaceuticals (ASX: $NEU) Unveils A$50 Million Share Buy-Back Program
    Health Care
    $neu
    Neuren Pharmaceuticals (ASX: $NEU) Unveils A$50 Million Share Buy-Back ProgramNeuren Pharmaceuticals Limited (ASX: NEU) has announced a significant development for its shareholders: the initiation of an on-market share buy-back...
    November 14, 2024
    neuren-pharmaceuticals-asx-neu-reports-strong-q3-2024-results-neu
    Health Care $NEU
    Neuren Pharmaceuticals (ASX: $NEU) reports strong Q3 2024 resultsAchieves major sales milestones with DAYBUETM and advances NNZ-2591 development pipeline
    November 7, 2024
    neuren-pharmaceuticals-asx-neu-announces-temporary-trading-pause-neu
    Health Care $NEU
    Neuren Pharmaceuticals (ASX: $NEU) announces temporary trading pauseTrading paused pending further announcement from Neuren Pharmaceuticals, initiated by ASX Listings Compliance
    November 7, 2024
    neuren-pharmaceuticals-asx-neu-capitalizes-on-priority-review-voucher-sale-neu
    Health Care $NEU
    Neuren Pharmaceuticals (ASX: $NEU) capitalizes on priority review voucher saleSells Rare Pediatric Disease Priority Review Voucher for US$150 million through Acadia Pharmaceuticals partnership
    November 6, 2024
    neuren-pharmaceuticals-asx-neu-secures-health-canada-approval-for-rett-syndrome-treatment-neu
    Health Care $NEU
    Neuren Pharmaceuticals (ASX: NEU) secures Health Canada approval for Rett syndrome treatmentDAYBUETM becomes first approved treatment for Rett syndrome in Canada, expanding Neuren's market reach
    October 17, 2024
    neuren-asx-neu-announces-positive-phase-2-trial-results-in-angelman-syndrome-neu
    Health Care $NEU

    Neuren (ASX: $NEU) announces positive Phase 2 trial results in Angelman syndrome

    NNZ-2591 shows statistically significant and clinically meaningful improvements in children with Angelman syndrome

    August 9, 2024
    neuren-pharmaceuticals-asx-neu-requests-trading-halt-for-pending-phase-2-clinical-trial-announcement-neu
    Health Care $NEU

    Neuren Pharmaceuticals (ASX: $NEU) requests trading halt for pending Phase 2 clinical trial announcement

    Company requests halt for analysis of Phase 2 clinical trial in Pitt Hopkins syndrome

    May 23, 2024
    neuren-asx-neu-reports-a8-0-million-net-cash-from-operating-activities-in-q1-2024-neu
    Health Care $NEU

    Neuren (ASX: $NEU) reports A$8.0 million net cash from operating activities in Q1 2024

    Guidance for net sales of US$370-420 million for DAYBUETM in 2024

    April 24, 2024
    neuren-asx-neu-reports-trofinetide-new-drug-submission-for-rett-syndrome-accepted-for-priority-review-neu
    Health Care $NEU

    Neuren (ASX: $NEU) reports trofinetide new drug submission for Rett syndrome accepted for priority review

    Health Canada grants priority review for trofinetide new drug submission by Neuren's global partner Acadia Pharmaceuticals

    April 24, 2024

    NEU

    $NEU

    Neuren Pharmaceuticals (ASX: $NEU) reports strong Q3 2024 results

    Achieves major sales milestones with DAYBUETM and advances NNZ-2591 development pipeline

    NEU

    $NEU

    Neuren Pharmaceuticals (ASX: $NEU) announces temporary trading pause

    Trading paused pending further announcement from Neuren Pharmaceuticals, initiated by ASX Listings Compliance

    NEU

    $NEU

    Neuren Pharmaceuticals (ASX: $NEU) capitalizes on priority review voucher sale

    Sells Rare Pediatric Disease Priority Review Voucher for US$150 million through Acadia Pharmaceuticals partnership

    NEU

    $NEU

    Neuren Pharmaceuticals (ASX: NEU) secures Health Canada approval for Rett syndrome treatment

    DAYBUETM becomes first approved treatment for Rett syndrome in Canada, expanding Neuren's market reach

    NEU

    $NEU

    Neuren (ASX: $NEU) announces positive Phase 2 trial results in Angelman syndrome

    NNZ-2591 shows statistically significant and clinically meaningful improvements in children with Angelman syndrome

    NEU

    $NEU

    Neuren Pharmaceuticals (ASX: $NEU) requests trading halt for pending Phase 2 clinical trial announcement

    Company requests halt for analysis of Phase 2 clinical trial in Pitt Hopkins syndrome

    NEU

    $NEU

    Neuren (ASX: $NEU) reports A$8.0 million net cash from operating activities in Q1 2024

    Guidance for net sales of US$370-420 million for DAYBUETM in 2024

    NEU

    $NEU

    Neuren (ASX: $NEU) reports trofinetide new drug submission for Rett syndrome accepted for priority review

    Health Canada grants priority review for trofinetide new drug submission by Neuren's global partner Acadia Pharmaceuticals

    Related Companies
    BLOCK INC.
    $SQ2
    INSIGNIA FINANCIAL LTD
    $IFL
    DOMACOM LIMITED
    $DCL
    HARMONEY CORP LIMITED
    $HMY
    MICROEQUITIES ASSET MANAGEMENT GROUP LIMITED
    $MAM

    ASX News, First
    & Fast.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    By clicking Subscribe, you agree to our Terms & Conditions
    © 2024 Stock Piper.
    All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support

    Socials

    Facebook
    Twitter
    LinkedIn
    © 2024 Stock Piper. All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support
    © 2024 Stock Piper. All rights reserved
    Social Media Auto Publish Powered By : XYZScripts.com
    Stock Piper AI Index
    Subscribe
    Join FREE Newsletter

    Stock Piper AI Index Coming Soon!

    Join our Newsletter to gain exclusive insight and be notified once we are live.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    Get all the latest market updates straight to your inbox.

    By clicking Subscribe, you agree to our Terms & Conditions